• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

Orphan designation lights pathway to epilepsy drug development

Sep. 21, 2015
By Marie Powers
Moving into a chronic indication with numerous approved drugs is a challenge that gives pause to drugmakers, even when millions of patients can't tolerate or don't respond to existing therapies. When the indication additionally falls into the central nervous system (CNS) space, which has bedeviled dozens of drug development attempts in recent years, all but the boldest in the field tend to focus their efforts elsewhere.
Read More

TG seeks twofer in SPA for combo CLL phase III trial

Sep. 18, 2015
By Marie Powers
TG Therapeutics Inc. will seek to carry two candidates in its pipeline across the goal line in a single play after reaching agreement with the FDA on a special protocol assessment (SPA) for the design of a phase III study combining TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, a glycoengineered once-daily phosphoinositide-3-kinase (PI3K)-delta inhibitor, to treat chronic lymphocytic leukemia (CLL).
Read More

Xenoport drug hits phase II psoriasis endpoints but dinged on diarrhea

Sep. 16, 2015
By Marie Powers
A pre-market lift for shares of Xenoport Inc. (NASDAQ:XNPT) quickly deflated Tuesday following release of preliminary top-line results from the phase II trial of XP23829 in moderate to severe chronic plaque-type psoriasis. Shares closed at $4.84 for a loss of $1.89, or 28.1 percent.
Read More

‘MAGR’ discovery for Gencia with potential $500M Takeda collaboration

Sep. 16, 2015
By Marie Powers
Gencia LLC, a nine-person biotech based in Charlottesville, Va., made an auspicious debut on the biotech stage with a potential $500 million deal with Takeda Pharmaceutical Co. Ltd. to develop a class of small-molecule drugs called mitochondrial agonists of the glucocorticoid receptor, or MAGRs. Gencia said its compounds may offer the benefits of conventional glucocorticoids but with improved potency and safety.
Read More

Raptor Pharmaceutical rapped after RP103 disappoints in pediatric NASH

Sep. 15, 2015
By Marie Powers
Raptor Pharmaceutical Corp.'s program to advance RP103 (cysteamine bitartrate delayed-release) in pediatric nonalcoholic steatohepatitis (NASH) "has always been a little bit left of center," president and CEO Julie Anne Smith maintained Monday. "Our core competency is in rare diseases.
Read More

Collegium ‘Xtampza’s out doubts in FDA adcom, wins unanimous endorsement

Sep. 14, 2015
By Marie Powers
Taking its turn before a joint meeting of the Anesthetic and Analgesic Drug Products and the Drug Safety and Risk Management advisory committees (adcom), Collegium Pharmaceutical Inc. faced many of the same questions about its tamper-resistant, extended-release (ER) oxycodone candidate, Xtampza (formerly COL-003), that Purdue Pharma LP incurred the previous day about Avridi, its immediate-release oxycodone tablet.
Read More

‘MAGR’ discovery for Gencia with potential $500M Takeda collaboration

Sep. 11, 2015
By Marie Powers
Gencia LLC, a nine-person biotech based in Charlottesville, Va., made an auspicious debut on the biotech stage with a potential $500 million deal with Takeda Pharmaceutical Co. Ltd. to develop a class of small-molecule drugs called mitochondrial agonists of the glucocorticoid receptor, or MAGRs. Gencia said its compounds may offer the benefits of conventional glucocorticoids but with improved potency and safety.
Read More

Cipla doubles down on U.S. market with $550M shopping spree

Sep. 9, 2015
By Marie Powers
Cipla Ltd., through its UK unit, Cipla EU, inked agreements to acquire the U.S.-based generics company, Invagen Pharmaceuticals Inc., and consulting firm Exelan Pharmaceuticals Inc., in an all-cash deal valued at $550 million. The move represented the second big shift in the U.S. generics market in as many days, coming 24 hours after Lannett Co. Inc., of Philadelphia, said it was purchasing Kremers Urban Pharmaceuticals Inc., of Princeton, N.J. – the U.S. specialty generic pharmaceuticals subsidiary of UCB SA, of Brussels – for $1.23 billion up front and undisclosed contingency payments.
Read More

Cipla doubles down on U.S. market with $550M shopping spree

Sep. 8, 2015
By Marie Powers
Cipla Ltd., through its UK unit, Cipla EU, inked agreements to acquire the U.S.-based generics company, Invagen Pharmaceuticals Inc., and consulting firm Exelan Pharmaceuticals Inc., in an all-cash deal valued at $550 million.
Read More

Incyte buys into future with potential $795M Jiangsu Hengrui deal

Sep. 3, 2015
By Marie Powers
Incyte Corp. leveraged its positive cash flow to invest in its immuno-oncology (I-O) future through a license and collaboration agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop and commercialize anti-PD-1 monoclonal antibody SHR-1210.
Read More
Previous 1 2 … 74 75 76 77 78 79 80 81 82 … 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe